Tag: hybridization chain reaction

The advent of antibody–drug conjugates (ADCs) has already transformed the landscape of targeted cancer therapy, offering a compelling strategy for directing cytotoxic payloads specifically to tumour cells. Yet ADCs carry well-documented limitations: the large molecular weight of immunoglobulins constrains their penetration into solid tumour tissue, and their reliance on a single surface biomarker for recognition…